2. Search Result
Search Result
Results for "

Aβ42 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

58

Inhibitors & Agonists

1

Fluorescent Dye

8

Peptides

6

Natural
Products

5

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4295
    Z-Phe-Ala-diazomethylketone

    PADK

    		 Cathepsin γ-secretase Neurological Disease
    Z-Phe-Ala-diazomethylketone binds directly to Aβ42 monomers and small oligomers. Z-Phe-Ala-diazomethylketone inhibits the formation of Aβ42 dodecamers and inhibits Aβ42 fibril formation in the solution. Z-Phe-Ala-diazomethylketone has the potential for neurodegenerative disorders research .
    Z-Phe-Ala-diazomethylketone
  • HY-N6640
    2-O-Acetyl-20-hydroxyecdysone

    20-Hydroxyeedysone 2-acetate

    		 Amyloid-β Neurological Disease
    2-O-Acetyl-20-hydroxyecdysone, an ecdysterones in insects and terrestrial plants, inhibits amyloid-β42 (Aβ42)-induced cytotoxicity. 2-O-Acetyl-20-hydroxyecdysone could decrease Aβ oligomer formation through promotion of fibrogenesis, transforming Aβ oligomers to the low-toxicity fibrils .
    2-O-Acetyl-20-hydroxyecdysone
  • HY-103241
    Ro 90-7501
    3 Publications Verification

    		 Amyloid-β ATM/ATR Phosphatase Apoptosis Neurological Disease Cancer
    Ro 90-7501 is an amyloid β42 (Aβ42) fibril assembly inhibitor that reduces Aβ42-induced cytotoxicity (EC50 of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response . Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .
    Ro 90-7501
  • HY-144752
    cSPM

    Cyclic spermine

    		 Amyloid-β Neurological Disease
    cSPM (Cyclic spermine) is a Aβ42 inhibitor. cSPM could suppress the aggregation of three different peptides, Aβ42, amylin and insulin, and decreases cytotoxicity .
    cSPM
  • HY-173282
    Aβ aggregation-IN-2

    		Amyloid-β Neurological Disease
    Aβ aggregation-IN-2 (Compound 8i) is an inhibitor of amyloid-β protein (Aβ42) aggregation, showing approximately 91% inhibition of Aβ42 aggregation at 25 μM. It also exhibits Aβ42 disaggregation effects and antioxidant activity. Aβ aggregation-IN-2 can be used for research in the field of Alzheimer's disease .
    Aβ aggregation-IN-2
  • HY-169614
    2002-G12

    		Amyloid-β Neurological Disease
    2002-G12 (compound 5a) is an Aβ42 inhibitor that can reduce Aβ42 toxicity by 76%. 2002-G12 can be used in Alzheimer's research .
    2002-G12
  • HY-146139
    Aβ-IN-3

    		Amyloid-β Neurological Disease
    Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one .
    Aβ-IN-3
  • HY-146140
    Aβ-IN-4

    		Amyloid-β Neurological Disease
    Aβ-IN-4 (compound 12) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-4 inhibits Aβ42 aggregation. However, Aβ-IN-4 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-4 can not change the aggregation state of Aβ42 into a nontoxic one .
    Aβ-IN-4
  • HY-P10876
    mcK6A1

    		Amyloid-β Neurological Disease
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
    mcK6A1
  • HY-119196
    Caprospinol

    SP-233

    		 Amyloid-β Sigma Receptor Others
    Caprospinol (SP-233) is a steroid compound candidate based on the structure of 22R-hydroxycholesterol. It has multiple mechanisms of neuroprotection, including binding to β-amyloid protein (Aβ(42)), interacting with the mitochondrial respiratory chain, clearing Aβ(42) monomers, and acting as a σ-1 receptor ligand. It can cross the blood-brain barrier in vivo and restore cognitive impairment, and has the potential to inhibit Alzheimer's disease.
    Caprospinol
  • HY-P10799
    SLAFVDVLN

    		Amyloid-β Neurological Disease Metabolic Disease
    SLAFVDVLN, a molecular peptide, is a BACE-1 inhibitor with a Ki value of 94 nM. SLAFVDVLN can reduce Aβ42 production .
    SLAFVDVLN
  • HY-153255
    BACE1-IN-13

    		Beta-secretase Neurological Disease
    BACE1-IN-13 (Compound 36) is an orally active BACE1 inhibitor with an IC50 value of 2.9 nM. BACE1-IN-13 is highly potent in hAβ42 cell (IC50 = 1.3 nM). BACE1-IN-13 has cardiovascularly safty and elicits sustained Aβ42 reduction in mouse and dog animal models .
    BACE1-IN-13
  • HY-120449
    AZ4800

    		Amyloid-β Others
    AZ4800 is a combined inhibitor of two targets in the amyloid precursor protein processing process with additive lowering activity on Aβ42 levels in vitro and in vivo.
    AZ4800
  • HY-P3793
    Amyloid β-Protein (33-42) (TFA)

    		Amyloid-β Neurological Disease
    Amyloid β-Protein (33-42) TFA is the residues 33-42 fragment of the β-amyloid protein. Amyloid β-Protein (33-42) TFA inhibits Aβ42-induced toxicity .
    Amyloid β-Protein (33-42) (TFA)
  • HY-114508
    Dihydrochalcone

    3-Phenylpropiophenone; β-Phenylpropiophenone

    		 Amyloid-β Neurological Disease
    Dihydrochalcone (3-Phenylpropiophenone) is a BBB-penatrable Aβ aggregation inhibitor. Dihydrochalcone destabilizes Aβ17-42 protofibrils by disrupting the β-sheet of β1 region. Dihydrochalcone destabilizes both U-shaped Aβ40/Aβ42 protofibrils and S-shaped Aβ42 protofibrils by binding to the protofibril cavity. Dihydrochalcone is the main component of daemonorops draco tree .
    Dihydrochalcone
  • HY-N0373
    Licochalcone B
    5+ Cited Publications

    		 Amyloid-β Apoptosis NOD-like Receptor (NLR) Neurological Disease
    Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .
    Licochalcone B
  • HY-P3307
    Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2

    		Tau Protein Neurological Disease
    Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2 is serum stable, non-toxic to neuronal cells, and selectivity inhibits the fibrilization of tau over Aβ42.
    Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2
  • HY-N0116
    Hematoxylin
    5+ Cited Publications

    Natural Black 1; Haematoxylin

    		 Amyloid-β Others
    Hematoxylin (Natural Black 1), a naturally occurring flavonoid compound derived from Caesalpinia sappan Linn.. Hematoxylin is a nuclear stain in histology and is also a potent Aβ42 fibrillogenesis inhibitor with an IC50 of 1.6 μM.
    Hematoxylin
  • HY-N0373R
    Licochalcone B (Standard)

    		Amyloid-β Apoptosis NOD-like Receptor (NLR) Neurological Disease
    Licochalcone B (Standard) is the analytical standard of Licochalcone B. This product is intended for research and analytical applications. Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .
    Licochalcone B (Standard)
  • HY-B0034
    Donepezil Hydrochloride
    10+ Cited Publications

    E2020

    		 Cholinesterase (ChE) Neurological Disease Cancer
    Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC50 of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .
    Donepezil Hydrochloride
  • HY-123228
    CHF5022

    		Amyloid-β Neurological Disease
    CHF5022 is an inhibitor of Aβ42 secretion (IC50=92 μM). CHF5022 retains a modest activity on Aβ40 at non-cytotoxic concentrations (−22.2±4.8% at 100 μM) .
    CHF5022
  • HY-153986
    AEP-IN-2

    		Cathepsin Neurological Disease
    AEP-IN-2 is an asparagine endopeptidase (AEP) inhibitor via block AEP cleavage of APP and Tau. AEP-IN-2 has oral activity and decreases Aβ40 and Aβ42 and p-Tau levels .
    AEP-IN-2
  • HY-146251
    BuChE-IN-6

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    BuChE-IN-6 (compound 1b) is a potent and selective BuChE (butyrylcholinesterase) inhibitor, with IC50 values of 0.46 and 0.51 μM for eqBuChE and hBuChE, respectively. BuChE-IN-6 also inhibits Aβ42 self-aggregation .
    BuChE-IN-6
  • HY-172101
    AChE/MAO-B-IN-7

    		Cholinesterase (ChE) Monoamine Oxidase Amyloid-β Neurological Disease
    AChE/MAO-B-IN-7 (VAV-8) is a blood-brain permeable dual inhibitor of acetylcholinesterase (AchE) and MAO-B agent. AChE/MAO-B-IN-7 can also inhibit Aβ42 aggregation for use in Alzheimer's disease (AD) research .
    AChE/MAO-B-IN-7
  • HY-10016
    E 2012
    5+ Cited Publications

    		 γ-secretase Neurological Disease
    E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat .
    E 2012
  • HY-150049
    γ-Secretase modulator 13

    		Amyloid-β Neurological Disease
    γ-Secretase modulator 13 (compound 4) is a gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC50 value of 163 nM. γ-Secretase modulator 13 can be used in the study of Alzheimer's disease .
    γ-Secretase modulator 13
  • HY-W010041
    Scyllo-Inositol

    		Amyloid-β Endogenous Metabolite Neurological Disease
    Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of amyloid-β peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model .
    Scyllo-Inositol
  • HY-10009
    Semagacestat
    10+ Cited Publications

    LY450139

    		 γ-secretase Amyloid-β Notch Neurological Disease
    Semagacestat is a γ-secretase inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC50s of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC50 of 14.1 nM. Semagacestat can be used for the research of alzheimer's disease .
    Semagacestat
  • HY-B0034S
    Donepezil-d5 hydrochloride

    E2020-d5

    		 Cholinesterase (ChE) Neurological Disease
    Donepezil-d5 (hydrochloride) is deuterium labeled Donepezil (Hydrochloride). Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC50 of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE[1]. Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity[2].
    Donepezil-d5 hydrochloride
  • HY-B0034S1
    Donepezil-d4 hydrochloride

    E2020-d4

    		 Cholinesterase (ChE) Neurological Disease
    Donepezil-d4 (hydrochloride) is the deuterium labeled Donepezil hydrochloride. Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC50 of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE[1]. Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity[2].
    Donepezil-d4 hydrochloride
  • HY-N12321
    2',3'-Dihydroxy-4',6'-dimethoxychalcone

    		Others Metabolic Disease
    2',3'-Dihydroxy-4',6'-dimethoxychalcone (compound 1) can inhibit Amyloid β-protein (Aβ42) fibrillization and aggregation. 2',3'-Dihydroxy-4',6'-dimethoxychalcone has oral activity and can be detected in the brain .
    2',3'-Dihydroxy-4',6'-dimethoxychalcone
  • HY-17406
    Tolcapone
    2 Publications Verification

    Ro 40-7592

    		 COMT Amyloid-β Apoptosis Neurological Disease Cancer
    Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .
    Tolcapone
  • HY-17406S
    Tolcapone-d7

    Ro 40-7592 d7

    		 Isotope-Labeled Compounds COMT Amyloid-β Neurological Disease
    Tolcapone-d7 is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells[1][2].
    Tolcapone-d7
  • HY-B0034R
    Donepezil (Hydrochloride) (Standard)

    		Cholinesterase (ChE) Neurological Disease Cancer
    Donepezil (Hydrochloride) (Standard) is the analytical standard of Donepezil (Hydrochloride). This product is intended for research and analytical applications. Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC50 of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .
    Donepezil (Hydrochloride) (Standard)
  • HY-150050
    gamma-secretase modulator 5

    		Amyloid-β Neurological Disease
    gamma-secretase modulator 5 (compound 22d) is a brain-penetrant gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC50 value of 60 nM. gamma-secretase modulator 5 can be used in the study of Alzheimer's disease .
    gamma-secretase modulator 5
  • HY-162832
    Amyloid-β-IN-1

    		Amyloid-β Neurological Disease
    Amyloid-β-IN-1 (compound 13) is a synthetic peptide containing the hydrophobic C-terminal region "VVIA-NH2" and its reverse sequence "AIVV-NH2" of Aβ42, which is an Aβ inhibitor. Amyloid-β-IN-1 can inhibit Aβ aggregation and has neuroprotective effects .
    Amyloid-β-IN-1
  • HY-103442
    CGP52411

    DAPH

    		 EGFR Amyloid-β Neurological Disease Cancer
    CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC50 of 0.3 μM. CGP52411 blocks the toxic influx of Ca 2+ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease .
    CGP52411
  • HY-116942
    2002-H20

    		Amyloid-β Neurological Disease
    2002-H20 is an inhibitor of Aβ42-induced cytotoxicity, with the activity of reducing the cytotoxicity of Alzheimer's disease Aβ peptide by binding to it. 2002-H20 protects cells and reduces Aβ toxicity by promoting fibril formation, possibly by accelerating Aβ aggregation. The screening method of 2002-H20 effectively identifies compounds that reduce Aβ toxicity and presents potential inhibitory leads .
    2002-H20
  • HY-173144
    AChE-IN-85

    		Cholinesterase (ChE) Reactive Oxygen Species Interleukin Related Lactate Dehydrogenase Amyloid-β Neurological Disease Inflammation/Immunology
    AChE-IN-85 (Compound 7k) is an AChE inhibitor with an IC50 of 0.083 μM. AChE-IN-85 can inhibit the release of NO, the production of TNF-α and IL-1β, the levels of LDH and ROS, as well as the aggregation of Aβ42. AChE-IN-85 has anti-inflammatory and neuroprotective effects and can be used in the research of diseases such as Alzheimer's disease .
    AChE-IN-85
  • HY-14533
    K 01-162

    K162

    		 Amyloid-β Neurological Disease
    K 01-162 (K162) inhibits the fibril formation of Aβ peptides and eliminates their neurotoxicity. K 01-162 binds with Aβ42 peptide with an EC50 value of 80 nM. K 01-162 binds directly to AβO with a KD value of 19 μM. K 01-162 is capable of penetrating the brain and can be used for the research of Alzheimer’s disease .
    K 01-162
  • HY-171347
    gamma-secretase modulator 6

    		γ-secretase Amyloid-β Neurological Disease
    gamma-secretase modulator 6 (Example 50) is a gamma-secretase modulator. gamma-secretase modulator 6 inhibits Aβ42 secretion in HEK cell line stably expressing APP (Aβ amyloid precursor protein) (pIC50: 8.1). gamma-secretase modulator 6 can be used for research of Alzheimer's disease .
    gamma-secretase modulator 6
  • HY-17406S1
    Tolcapone-d4

    Ro 40-7592-d4

    		 Isotope-Labeled Compounds COMT Amyloid-β Apoptosis Neurological Disease Cancer
    Tolcapone-d4 is the deuterium labeled Tolcapone. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver[1]. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis[2]. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma[3].
    Tolcapone-d4
  • HY-17406R
    Tolcapone (Standard)

    Ro 40-7592 (Standard)

    		 COMT Amyloid-β Apoptosis Neurological Disease Cancer
    Tolcapone (Standard) is the analytical standard of Tolcapone. This product is intended for research and analytical applications. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .
    Tolcapone (Standard)
  • HY-10009R
    Semagacestat (Standard)

    LY450139 (Standard)

    		 γ-secretase Amyloid-β Notch Neurological Disease
    Semagacestat (Standard) is the analytical standard of Semagacestat. This product is intended for research and analytical applications. Semagacestat is a γ-secretase inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC50s of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC50 of 14.1 nM. Semagacestat can be used for the research of alzheimer's?disease[1].
    Semagacestat (Standard)
  • HY-50845
    Avagacestat
    2 Publications Verification

    BMS-708163

    		 γ-secretase Notch Cancer
    Avagacestat (BMS-708163) is a potent inhibitor of γ-secretase, with IC50s of 0.27 nM and 0.30 nM for Aβ42 and Aβ40 inhibition; Avagacestat (BMS-708163) also inhibits NICD (Notch IntraCellular Domain) with IC50 of 0.84 nM and shows weak inhibition of CYP2C19, with IC50 of 20 μM. Avagacestat can be used for Alzheimer disease research.
    Avagacestat
  • HY-13027
    DAPT
    Maximum Cited Publications
    107 Publications Verification

    GSI-IX

    		 Organoid γ-secretase Amyloid-β Autophagy Notch Apoptosis Neurological Disease Inflammation/Immunology Cancer
    DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment .
    DAPT
  • HY-14399
    Itanapraced
    1 Publications Verification

    CHF5074; CSP-1103

    		 γ-secretase Apoptosis Neurological Disease
    Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease .
    Itanapraced
  • HY-100604
    JNJ-40418677

    		γ-secretase Amyloid-β Neurological Disease
    JNJ-40418677 is an orally active modulator of γ-secretase, can cross the blood-brain barrier. JNJ-40418677 inhibits Aβ42 and NS2B-NS3 protease, with IC50s of 200 nM and 3.9 μM, respectively. JNJ-40418677 displays good biological tolerance, can be use for Alzheimer’s disease research .
    JNJ-40418677
  • HY-137370
    2-Hexynyl-5′-N-ethylcarboxamidoadenosine

    HENECA; 2-Hexynyl-NECA

    		 Adenosine Receptor Amyloid-β Neurological Disease
    2-Hexynyl-5′-N-ethylcarboxamidoadenosine (HENECA) is a selective A2A adenosine receptor agonist. 2-Hexynyl-5′-N-ethylcarboxamidoadenosine increases intracellular cAMP level, and inhibits TNFα-evoked MMP-3 release. 2-Hexynyl-5′-N-ethylcarboxamidoadenosine induces Aβ42 production in SH-SY5Y cells .
    2-Hexynyl-5′-N-ethylcarboxamidoadenosine
  • HY-P10824
    RI-OR2-TAT

    		Amyloid-β Neurological Disease
    RI-OR2-TAT is a brain-penetrant inhibitor of β-Amyloid oligomerization, which is produced by adding the HIV protein transduction domain TAT to RI-OR2. RI-OR2-TAT binds to Aβ42 fibrils with a Kd value of 58-125 nM. RI-OR2-TAT reduces Aβ aggregation and plaque levels, reduces activation of microglia and oxidative damage, and increases the number of young neurons in the dentate gyrus .
    RI-OR2-TAT

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: